查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1466564

抗體片段市場：按類型、抗體類型、應用分類 - 2024-2030 年全球預測

Antibody Fragments Market by Type (F(ab) Fragments, F(ab')2 Fragments, Single Domain Antibody Fragments (sdAbs)), Antibody Type (Monoclonal, Polyclonal), Application - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2023年抗體片段市場規模為77.2億美元，預計2024年將達到80.7億美元，2030年將達到104.2億美元，複合年成長率為4.36%。

抗體片段是抗體的一部分，可以與特定類型的抗原結合，抗原是體內引起免疫反應的外來物質。抗體片段通常衍生完整抗體，並透過酵素消化或基因工程技術開發。這個市場開拓的關鍵驅動力是擴大採用標靶治療來治療自體免疫疾病等慢性疾病。遺傳和生化技術的進步也為增強這些片段的生產和工程化鋪平了道路，從而推動了成長。研發資金的不斷增加和強大的醫療基礎設施（尤其是在已開發國家）促進了整體市場的成長。然而，生產和精製抗體片段的高成本可能會限制市場成長。新興市場的監管挑戰和缺乏認知也是潛在的成長阻礙因素。新的可能性包括使用抗體片段開發創新藥物並將其用於開拓的疾病領域。此外，新興市場製藥和生物技術工作的擴展和整合也為抗體片段市場的成長帶來了重大機會。

主要市場統計
基準年[2023] 77.2億美元
預測年份 [2024] 80.7億美元
預測年份 [2030] 104.2億美元
複合年成長率（%） 4.36%

單域抗體 (sdAb) 由於其穩定性和靈活的結合而在應用中迅速普及。

F(ab) 片段是具有單一抗原結合位點 (Fab) 的小抗體片段。由於它沒有保守的 Fc 區，因此不能透過抗體依賴性細胞毒性來破壞細胞。應用於影像診斷、診斷藥物等。與 F(ab) 相比，F(ab')2 片段具有兩個抗原結合位點，使抗體能夠更牢固地與其標靶結合。與 F(ab)2 片段相比，F(ab')2 片段具有兩個抗原結合位點，可以更強地結合標靶。單域抗體 (sdAb) 以其高溶解度、熱穩定性和與酶活性位點結合的能力而聞名，在治療和研究中具有廣泛的用途。單鏈可變片段 (scFv) 具有與單株抗體類似的結合特異性。作為設計抗體衍生物的有效工具，它受到標靶藥物遞送和免疫治療的青睞。

抗體類型：單株抗體的使用由於其在標靶治療中的高特異性而不斷增加。

單株抗體 (MAb) 是由單一 B 細胞克隆產生的相同抗體。單株抗體對單一抗原決定簇具有特異性，具有高特異性、一致的品質和無限的供應。例子包括特定蛋白質的檢測和定量、腫瘤和自體免疫疾病等治療領域，以及細胞和組織的染色，在這些領域中，僅檢測感興趣的抗原很重要。多株抗體(PAb) 是體內不同 B 細胞克隆產生的抗體混合物，每種抗體識別抗原上的不同表位。其結果是產生一系列在某些條件下可能有益的反應。多株抗體是需要在檢測系統中提供強大訊號的研究的首選，例如蛋白質印跡、ELISA 和免疫組織化學。由於 PAb 在不同條件下可以結合多個表位，因此能夠耐受抗原構象的微小變化。可以提供比單株抗體更高的整體結合親和性。

應用 抗體片段在癌症治療的應用進展

抗體片段在癌症治療的應用被認為是癌症研究的突破。它們的小尺寸使它們能夠比完整抗體更有效地穿透並結合癌細胞。此外，它可以最大限度地減少對健康細胞造成附帶損害的風險，並提供更有針對性的治療方法。抗體片段在免疫力缺乏的治療中極為重要。抗體片段補償缺失或不足的抗體反應，並提高患者抵抗感染疾病的能力。它們還可以針對特定疾病生物標記進行設計，從而實現更個性化的治療。雖然癌症治療主要著重於針對性地清除癌細胞，免疫力缺乏使用抗體片段來增強人體的免疫反應。

區域洞察

由於持續的研究舉措為市場成長鋪平了道路，美洲在抗體片段市場中佔有重要地位。這些國家的購買行為很大程度上是由個人化醫療的出現所推動的，特別關注特異性疾病的應用。隨著私人和政府對下一代醫療保健技術的投資增加，預計將進一步成長。由於健康意識的提高和政府的公共衛生舉措，歐洲、中東和非洲 (EMEA) 是一個快速成長的抗體片段市場。這些地區與文明病呈上升趨勢，醫療保健領域需要創新的治療方法。歐盟國家和中東地區正在對診斷技術和研究進行大量投資，提供了廣泛的市場潛力。亞太地區是一個新興的醫療保健影響者和對抗體片段的需求不斷成長的地區。該領域不斷增加的研發投資顯示該地區市場成長前景廣闊。該地區的客戶行為揭示了對治療應用的傾向，許多製造商希望利用這一點，進一步推動該地區的市場成長。

FPNV定位矩陣

FPNV定位矩陣對於評估抗體片段市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標，以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估，供應商被分為四個成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市場佔有率分析

市場佔有率分析是一種綜合工具，可以對抗體片段市場供應商的現狀進行深入而深入的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻，以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外，該分析還提供了對該行業競爭特徵的寶貴見解，包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略，從而在市場上獲得競爭優勢。

本報告在以下方面提供了寶貴的見解：

1. 市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2. 市場開拓：我們深入研究利潤豐厚的新興市場，並分析其在成熟細分市場的滲透率。

3. 市場多元化：提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。

4.競爭力評估與資訊：對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況、製造能力等進行全面評估。

5. 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告解決了以下關鍵問題：

1. 抗體片段市場的市場規模與預測是多少？

2.抗體片段市場預測期內需要考慮投資的產品、細分市場、應用和領域有哪些？

3.抗體片段市場的技術趨勢和法規結構是什麼？

4.抗體片段市場主要廠商的市場佔有率為何？

5. 進入抗體片段市場的合適型態和策略手段是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 抗體片段在醫學診斷的使用增加
      • 各種癌症和感染疾病的發生率增加
      • 藥物發現活動的增加
    • 抑制因素
      • 抗體片段核准的嚴格監管指南
    • 機會
      • 抗體片段臨床開發進展
      • 先進重組DNA技術簡介
    • 任務
      • 抗癌免疫療法療效不足且副作用大
  • 市場區隔分析
    • 類型：由於結合穩定性和彈性，從應用角度來看，單域抗體片段（sdAb）的使用正在迅速增加
    • 抗體類型：標靶治療的高特異性擴大了單株抗體的用途
    • 應用：抗體片段在癌症治療中應用的演變
  • 市場擾動分析
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 價格分析
  • 技術分析
  • 專利分析
  • 貿易分析
  • 法規結構分析

第6章抗體片段市場：依類型

  • F(ab) 片段
  • F(ab')2 片段
  • 單域抗體片段 (sdAb)
  • 單鏈可變片段（scFv）

第7章抗體片段市場：按抗體類型

  • 單複製
  • 多克隆抗體

第8章抗體片段市場：依應用分類

  • 癌症
  • 免疫力缺乏

第9章美洲抗體片段市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太抗體片段市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章 歐洲、中東和非洲抗體片段市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • Lupin 和 Amman Pharma 合作獨家經銷雷珠單抗
    • 伯明罕血小板集團推出突破性「奈米抗體」技術
    • Atovia 是一家加州新創生技公司，成立的目的是重新思考藥物如何與目標結合。
  • 戰略分析和建議

第13章競爭產品組合

  • 主要企業簡介
  • 主要產品系列
Product Code: MRR-F927BA461FE0

[189 Pages Report] The Antibody Fragments Market size was estimated at USD 7.72 billion in 2023 and expected to reach USD 8.07 billion in 2024, at a CAGR 4.36% to reach USD 10.42 billion by 2030.

Antibody fragments refer to parts of antibodies capable of binding to specific types of antigens, the foreign substances in the body that induce an immune response. Antibody fragments are usually derivatives from whole antibodies and are developed through enzyme digestion or genetic engineering techniques. The primary driver of this market development is the increasing adoption of targeted therapies for treating chronic conditions, such as autoimmune diseases. Advancements in genetic and biochemical technologies have also paved the way for enhanced production and engineering of these fragments, boosting growth. A constant increase in R&D funding and robust healthcare infrastructure, especially in developed countries, contributed to overall market growth. However, the high costs of producing and purifying antibody fragments can restrict market growth. Regulatory challenges and lack of awareness in emerging markets also pose potential growth restrictions. New avenues for potential opportunities include the development of innovative drugs using antibody fragments and their usage in untapped disease areas. Additionally, the expansion and consolidation of pharmaceutical and biotechnological efforts in emerging markets also present significant opportunities for growth in the antibody fragments market.

KEY MARKET STATISTICS
Base Year [2023] USD 7.72 billion
Estimated Year [2024] USD 8.07 billion
Forecast Year [2030] USD 10.42 billion
CAGR (%) 4.36%

Type: Burgeoning usage of single domain antibody fragments (sdAbs) in terms of applications due to their stability and flexibility in binding

F(ab) Fragments are small antibody fragments that contain one antigen-binding (Fab) site. It does not present the conserved Fc region; therefore, it cannot destroy cells through antibody-dependent cellular cytotoxicity. Applications include imaging and diagnostics. F(ab')2 Fragments, compared to F(ab), contain two antigen-combining sites, enabling the antibody to bind more vigorously to its targets. It is appreciated for allowing a more concentrated tracking accuracy in in-vivo imaging. Single domain antibody fragments (sdAbs) are known for their high solubility, thermal stability, and ability to bind to enzyme active sites, making their uses variegated in therapeutics and undergoing research. Single-chain variable fragments (scFvs) have binding specificity similar to monoclonal antibodies. They are preferred for targeted drug delivery and immunotherapy as efficient tools for the design of antibody derivatives.

Antibody Type: Proliferating utilization of monoclonal antibodies owing to their high specificity in targeted therapeutics

Monoclonal antibodies(MAbs) are identical antibodies made by a single B-cell clone. They are specific for a single antigenic determinant, resulting in high specificity, consistently high quality, and unlimited supply. On a needs-based perspective, monoclonal antibodies are preferred in situations necessitating a high degree of specificity, such as in assays for detection and quantification of specific proteins, therapeutic areas such as oncology, autoimmune disorders, and in cell and tissue staining where it's critical to detect only the antigen of interest. Polyclonal antibodies (PAbs) are a mix of antibodies produced by different B cell clones in the body, each recognizing a different epitope of an antigen. This results in a broad-spectrum response that can be beneficial under certain conditions. Polyclonal antibodies are preferred in research requiring robust signals in detection systems such as Western blot, ELISA, or immunohistochemistry. Their capacity to bind multiple epitopes under varying conditions makes the PAbs more forgiving to slight changes in antigen conformation. It can offer a higher overall binding affinity than monoclonal antibodies.

Application: Evolving application of antibody fragments in cancer therapy

Antibody fragments in cancer therapy have been regarded as a breakthrough in oncology research. Their small size makes them penetrate and bind to cancer cells more efficiently than whole antibodies. Moreover, they minimize the risk of collateral damage to healthy cells, offering a more targeted treatment approach. Antibody fragments have been crucial in the treatment of immunodeficiencies. They help replace missing or inadequate antibody responses, improving the patient's ability to fight off infections. They offer more personalized treatment owing to their ability to be engineered to target specific disease biomarkers. Cancer treatment mainly focuses on the targeted elimination of cancer cells, whereas, in immunodeficiencies, antibody fragments are employed to boost the body's immune response.

Regional Insights

The Americas has a significant landscape in the antibody fragments market owing to ongoing research initiatives that pave the way for the market's growth. The purchasing behavior in these countries is predominantly driven by the advent of personalized medicine, with a notable focus on disease-specific applications. With the rising private and government entities' investments in next-generation healthcare technologies, further growth is anticipated. Europe, the Middle East, and Africa (EMEA) exhibit a burgeoning market for antibody fragments, driven by a rise in health consciousness and governmental initiatives for public health. The increase in lifestyle diseases in these regions has necessitated innovative therapeutics in the healthcare sector. EU countries and the Middle East are experiencing heavy investments in diagnostic technologies and research, thus promising market potential. The Asia Pacific region, home to emerging healthcare influencers, is witnessing a growing demand for antibody fragments. Increased investments in research & development in the field indicate a promising market growth in this region. The customer behavior in this region reveals an inclination towards therapeutic applications, which many manufacturers are looking to capitalize on, further increasing the market growth in the area.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Antibody Fragments Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Antibody Fragments Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Antibody Fragments Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Adaptimmune Therapeutics PLC, Aenova Group GmbH, Almac Group, Amgen Inc., Antikor Biopharma, Astellas Pharma Inc., Baxter International Inc., Biogen Inc., Bristol-Myers Squibb Company, Confo Therapeutics, Dyne Therapeutics, Eli Lilly and Company, Evonik Industries AG, F. Hoffmann-La Roche Ltd., Genentech, Inc., Gilde Healthcare, Johnson & Johnson Services, Inc., MoonLake Immunotherapeutics AG, Novartis AG, Numab AG, Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Antibody Fragments Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Type
    • F(ab) Fragments
    • F(ab')2 Fragments
    • Single Domain Antibody Fragments (sdAbs)
    • Single-chain Variable Fragments (scFvs)
  • Antibody Type
    • Monoclonal
    • Polyclonal
  • Application
    • Cancer
    • Immunodeficiencies
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Antibody Fragments Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Antibody Fragments Market?

3. What are the technology trends and regulatory frameworks in the Antibody Fragments Market?

4. What is the market share of the leading vendors in the Antibody Fragments Market?

5. Which modes and strategic moves are suitable for entering the Antibody Fragments Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing use of antibody fragments in medical diagnostics
      • 5.1.1.2. Rising incidences of various cancers and infectious diseases
      • 5.1.1.3. Increasing number of drug discovery activities
    • 5.1.2. Restraints
      • 5.1.2.1. Strict regulatory guidelines for the approval of antibody fragments
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in the clinical development of antibody fragments
      • 5.1.3.2. Introduction of advanced recombinant DNA technology
    • 5.1.4. Challenges
      • 5.1.4.1. Insufficient efficacy and adverse effects in anticancer immunotherapy
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Burgeoning usage of single domain antibody fragments (sdAbs) in terms of applications due to their stability and flexibility in binding
    • 5.2.2. Antibody Type: Proliferating utilization of monoclonal antibodies owing to their high specificity in targeted therapeutics
    • 5.2.3. Application: Evolving application of antibody fragments in cancer therapy
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Antibody Fragments Market, by Type

  • 6.1. Introduction
  • 6.2. F(ab) Fragments
  • 6.3. F(ab')2 Fragments
  • 6.4. Single Domain Antibody Fragments (sdAbs)
  • 6.5. Single-chain Variable Fragments (scFvs)

7. Antibody Fragments Market, by Antibody Type

  • 7.1. Introduction
  • 7.2. Monoclonal
  • 7.3. Polyclonal

8. Antibody Fragments Market, by Application

  • 8.1. Introduction
  • 8.2. Cancer
  • 8.3. Immunodeficiencies

9. Americas Antibody Fragments Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Antibody Fragments Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Antibody Fragments Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Lupin, Amman Pharma Collaborates for Exclusive Marketing of Ranibizumab
    • 12.3.2. Birmingham Platelet Group Delivers Breakthrough 'nanobody' Technology
    • 12.3.3. Attovia, a new California biotech, Launches with Plans to Rethink how Drugs Bind their Targets
  • 12.4. Strategy Analysis & Recommendation

13. Competitive Portfolio

  • 13.1. Key Company Profiles
  • 13.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. ANTIBODY FRAGMENTS MARKET RESEARCH PROCESS
  • FIGURE 2. ANTIBODY FRAGMENTS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. ANTIBODY FRAGMENTS MARKET DYNAMICS
  • FIGURE 7. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS ANTIBODY FRAGMENTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS ANTIBODY FRAGMENTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES ANTIBODY FRAGMENTS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES ANTIBODY FRAGMENTS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC ANTIBODY FRAGMENTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC ANTIBODY FRAGMENTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ANTIBODY FRAGMENTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ANTIBODY FRAGMENTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. ANTIBODY FRAGMENTS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 22. ANTIBODY FRAGMENTS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ANTIBODY FRAGMENTS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY F(AB) FRAGMENTS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY F(AB) FRAGMENTS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY F(AB')2 FRAGMENTS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY F(AB')2 FRAGMENTS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY SINGLE DOMAIN ANTIBODY FRAGMENTS (SDABS), BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY SINGLE DOMAIN ANTIBODY FRAGMENTS (SDABS), BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY SINGLE-CHAIN VARIABLE FRAGMENTS (SCFVS), BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY SINGLE-CHAIN VARIABLE FRAGMENTS (SCFVS), BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY MONOCLONAL, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY MONOCLONAL, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY POLYCLONAL, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY POLYCLONAL, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY IMMUNODEFICIENCIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY IMMUNODEFICIENCIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. AMERICAS ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 30. AMERICAS ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 31. AMERICAS ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
  • TABLE 32. AMERICAS ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
  • TABLE 33. AMERICAS ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 34. AMERICAS ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 35. AMERICAS ANTIBODY FRAGMENTS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 36. AMERICAS ANTIBODY FRAGMENTS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 37. ARGENTINA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 38. ARGENTINA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 39. ARGENTINA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
  • TABLE 40. ARGENTINA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
  • TABLE 41. ARGENTINA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 42. ARGENTINA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 43. BRAZIL ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 44. BRAZIL ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 45. BRAZIL ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
  • TABLE 46. BRAZIL ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
  • TABLE 47. BRAZIL ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 48. BRAZIL ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 49. CANADA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 50. CANADA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 51. CANADA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
  • TABLE 52. CANADA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
  • TABLE 53. CANADA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 54. CANADA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 55. MEXICO ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 56. MEXICO ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 57. MEXICO ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
  • TABLE 58. MEXICO ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
  • TABLE 59. MEXICO ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 60. MEXICO ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 61. UNITED STATES ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 62. UNITED STATES ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 63. UNITED STATES ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
  • TABLE 64. UNITED STATES ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
  • TABLE 65. UNITED STATES ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 66. UNITED STATES ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 67. UNITED STATES ANTIBODY FRAGMENTS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 68. UNITED STATES ANTIBODY FRAGMENTS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 70. ASIA-PACIFIC ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 71. ASIA-PACIFIC ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC ANTIBODY FRAGMENTS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC ANTIBODY FRAGMENTS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 77. AUSTRALIA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 78. AUSTRALIA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 79. AUSTRALIA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
  • TABLE 80. AUSTRALIA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
  • TABLE 81. AUSTRALIA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 82. AUSTRALIA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 83. CHINA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 84. CHINA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 85. CHINA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
  • TABLE 86. CHINA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
  • TABLE 87. CHINA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 88. CHINA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 89. INDIA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 90. INDIA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 91. INDIA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
  • TABLE 92. INDIA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
  • TABLE 93. INDIA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 94. INDIA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 95. INDONESIA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 96. INDONESIA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 97. INDONESIA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
  • TABLE 98. INDONESIA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
  • TABLE 99. INDONESIA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 100. INDONESIA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 101. JAPAN ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 102. JAPAN ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 103. JAPAN ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
  • TABLE 104. JAPAN ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
  • TABLE 105. JAPAN ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 106. JAPAN ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 107. MALAYSIA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 108. MALAYSIA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 109. MALAYSIA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
  • TABLE 110. MALAYSIA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
  • TABLE 111. MALAYSIA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 112. MALAYSIA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 113. PHILIPPINES ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 114. PHILIPPINES ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 115. PHILIPPINES ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
  • TABLE 116. PHILIPPINES ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
  • TABLE 117. PHILIPPINES ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 118. PHILIPPINES ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 119. SINGAPORE ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 120. SINGAPORE ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 121. SINGAPORE ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
  • TABLE 122. SINGAPORE ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
  • TABLE 123. SINGAPORE ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 124. SINGAPORE ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 125. SOUTH KOREA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 126. SOUTH KOREA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 127. SOUTH KOREA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
  • TABLE 128. SOUTH KOREA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
  • TABLE 129. SOUTH KOREA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 130. SOUTH KOREA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 131. TAIWAN ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 132. TAIWAN ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 133. TAIWAN ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
  • TABLE 134. TAIWAN ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
  • TABLE 135. TAIWAN ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 136. TAIWAN ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 137. THAILAND ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 138. THAILAND ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 139. THAILAND ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
  • TABLE 140. THAILAND ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
  • TABLE 141. THAILAND ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 142. THAILAND ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 143. VIETNAM ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 144. VIETNAM ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 145. VIETNAM ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
  • TABLE 146. VIETNAM ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
  • TABLE 147. VIETNAM ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 148. VIETNAM ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA ANTIBODY FRAGMENTS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA ANTIBODY FRAGMENTS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 157. DENMARK ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 158. DENMARK ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 159. DENMARK ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
  • TABLE 160. DENMARK ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
  • TABLE 161. DENMARK ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 162. DENMARK ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 163. EGYPT ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 164. EGYPT ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 165. EGYPT ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
  • TABLE 166. EGYPT ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
  • TABLE 167. EGYPT ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 168. EGYPT ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 169. FINLAND ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 170. FINLAND ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 171. FINLAND ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
  • TABLE 172. FINLAND ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
  • TABLE 173. FINLAND ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 174. FINLAND ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 175. FRANCE ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 176. FRANCE ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 177. FRANCE ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
  • TABLE 178. FRANCE ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
  • TABLE 179. FRANCE ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 180. FRANCE ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 181. GERMANY ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 182. GERMANY ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 183. GERMANY ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
  • TABLE 184. GERMANY ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
  • TABLE 185. GERMANY ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 186. GERMANY ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 187. ISRAEL ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 188. ISRAEL ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 189. ISRAEL ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
  • TABLE 190. ISRAEL ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
  • TABLE 191. ISRAEL ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 192. ISRAEL ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 193. ITALY ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 194. ITALY ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 195. ITALY ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
  • TABLE 196. ITALY ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
  • TABLE 197. ITALY ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 198. ITALY ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 199. NETHERLANDS ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 200. NETHERLANDS ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 201. NETHERLANDS ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
  • TABLE 202. NETHERLANDS ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
  • TABLE 203. NETHERLANDS ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 204. NETHERLANDS ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 205. NIGERIA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 206. NIGERIA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 207. NIGERIA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
  • TABLE 208. NIGERIA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
  • TABLE 209. NIGERIA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 210. NIGERIA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 211. NORWAY ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 212. NORWAY ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 213. NORWAY ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
  • TABLE 214. NORWAY ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
  • TABLE 215. NORWAY ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 216. NORWAY ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 217. POLAND ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 218. POLAND ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 219. POLAND ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
  • TABLE 220. POLAND ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
  • TABLE 221. POLAND ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 222. POLAND ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 223. QATAR ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 224. QATAR ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 225. QATAR ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
  • TABLE 226. QATAR ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
  • TABLE 227. QATAR ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 228. QATAR ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 229. RUSSIA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 230. RUSSIA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 231. RUSSIA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
  • TABLE 232. RUSSIA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
  • TABLE 233. RUSSIA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 234. RUSSIA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 235. SAUDI ARABIA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 236. SAUDI ARABIA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 237. SAUDI ARABIA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
  • TABLE 238. SAUDI ARABIA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
  • TABLE 239. SAUDI ARABIA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 240. SAUDI ARABIA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 241. SOUTH AFRICA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 242. SOUTH AFRICA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 243. SOUTH AFRICA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
  • TABLE 244. SOUTH AFRICA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
  • TABLE 245. SOUTH AFRICA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 246. SOUTH AFRICA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 247. SPAIN ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 248. SPAIN ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 249. SPAIN ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
  • TABLE 250. SPAIN ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
  • TABLE 251. SPAIN ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 252. SPAIN ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 253. SWEDEN ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 254. SWEDEN ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 255. SWEDEN ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
  • TABLE 256. SWEDEN ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
  • TABLE 257. SWEDEN ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 258. SWEDEN ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 259. SWITZERLAND ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 260. SWITZERLAND ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 261. SWITZERLAND ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
  • TABLE 262. SWITZERLAND ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
  • TABLE 263. SWITZERLAND ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 264. SWITZERLAND ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 265. TURKEY ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 266. TURKEY ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 267. TURKEY ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
  • TABLE 268. TURKEY ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
  • TABLE 269. TURKEY ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 270. TURKEY ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 271. UNITED ARAB EMIRATES ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 272. UNITED ARAB EMIRATES ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 273. UNITED ARAB EMIRATES ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
  • TABLE 274. UNITED ARAB EMIRATES ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
  • TABLE 275. UNITED ARAB EMIRATES ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 276. UNITED ARAB EMIRATES ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 277. UNITED KINGDOM ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 278. UNITED KINGDOM ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 279. UNITED KINGDOM ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
  • TABLE 280. UNITED KINGDOM ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
  • TABLE 281. UNITED KINGDOM ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 282. UNITED KINGDOM ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 283. ANTIBODY FRAGMENTS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 284. ANTIBODY FRAGMENTS MARKET, FPNV POSITIONING MATRIX, 2023